Agios Pharmaceuticals Inc (AGIO)
31.66
-0.15
(-0.47%)
USD |
NASDAQ |
Apr 24, 16:00
31.66
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Enterprise Value: 1.011B for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 1.011B |
| April 22, 2024 | 920.72M |
| April 19, 2024 | 882.50M |
| April 18, 2024 | 876.88M |
| April 17, 2024 | 854.41M |
| April 16, 2024 | 841.48M |
| April 15, 2024 | 867.33M |
| April 12, 2024 | 881.38M |
| April 11, 2024 | 944.32M |
| April 10, 2024 | 905.54M |
| April 09, 2024 | 892.62M |
| April 08, 2024 | 779.67M |
| April 05, 2024 | 771.24M |
| April 04, 2024 | 792.03M |
| April 03, 2024 | 822.94M |
| April 02, 2024 | 834.18M |
| April 01, 2024 | 844.85M |
| March 28, 2024 | 866.21M |
| March 27, 2024 | 859.46M |
| March 26, 2024 | 856.09M |
| March 25, 2024 | 890.93M |
| March 22, 2024 | 902.17M |
| March 21, 2024 | 922.40M |
| March 20, 2024 | 921.84M |
| March 19, 2024 | 913.97M |
| Date | Value |
|---|---|
| March 18, 2024 | 869.02M |
| March 15, 2024 | 905.54M |
| March 14, 2024 | 878.57M |
| March 13, 2024 | 908.92M |
| March 12, 2024 | 925.21M |
| March 11, 2024 | 953.87M |
| March 08, 2024 | 981.41M |
| March 07, 2024 | 985.90M |
| March 06, 2024 | 1.010B |
| March 05, 2024 | 985.90M |
| March 04, 2024 | 1.031B |
| March 01, 2024 | 1.036B |
| February 29, 2024 | 1.039B |
| February 28, 2024 | 1.115B |
| February 27, 2024 | 1.179B |
| February 26, 2024 | 1.070B |
| February 23, 2024 | 1.077B |
| February 22, 2024 | 896.55M |
| February 21, 2024 | 729.09M |
| February 20, 2024 | 745.95M |
| February 16, 2024 | 712.80M |
| February 15, 2024 | 729.09M |
| February 14, 2024 | 678.52M |
| February 13, 2024 | 636.37M |
| February 12, 2024 | 677.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.17M
Minimum
Jun 14 2022
3.415B
Maximum
Feb 11 2021
1.380B
Average
1.022B
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 16.98B |
| Blueprint Medicines Corp | 5.182B |
| Corcept Therapeutics Inc | 2.013B |
| Ionis Pharmaceuticals Inc | 5.050B |
| Madrigal Pharmaceuticals Inc | 3.824B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -95.94M |
| Revenue (Quarterly) | 7.103M |
| Total Expenses (Quarterly) | 113.38M |
| EPS Diluted (Quarterly) | -1.72 |
| Gross Profit Margin (Quarterly) | 91.75% |
| Profit Margin (Quarterly) | -1.35K% |
| Earnings Yield | -20.03% |
| Normalized Earnings Yield | -20.03 |